Treatment for myeloma bone disease

Clinical Cancer Research

Volumn 12, Issue 20 PART 2, 2006, Pages

  Yeh, Howard S ^a   Berenson, James R ^a   Guise, ^b   Pearse, ^b   Roodman, ^b   Suva, ^b   Clohisy, ^b   Coleman, ^b   Lipton, ^b  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE DESTRUCTION; BONE DISEASE; BONE TURNOVER; HUMAN; KYPHOPLASTY; MYELOMA; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PERCUTANEOUS VERTEBROPLASTY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; ORTHOPEDICS; RADIOPHARMACEUTICALS;

EID: 33750700802     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0681     Document Type: Review

References (83)

1. Mundy GR, Bertoline DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986;13:291-9.
2. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
3. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991;9:1397-402.
4. Kyle RA, Jowsey J, Kelly PJ, et al. Multiple myeloma bone disease: the comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 1975;293:1334-8.
5. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κ B. Blood 1996;87:1104.
6. Cozzolino F, Torcia M, Aldinucci D, et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989;74:380-7.
7. Kawano M, Tanaka H, Ishikawa H, et al. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 1989;73:2145-8.
8. Lacy MQ, Donovan KA, Heimbach JK, et al. Comparison of interleukin-1β expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999;93:300.
9. Garrett IR, Durie BG, Nedwin GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987;317:526.
10. Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999;94:3883.
11. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671.
12. Borset M, Hjorth-Hansen H, Seidel C, et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996;88:3998.
13. Suzuki A, Takahashi T, Okuno Y, et al. Production of parathyroid hormone-related protein by cultured human myeloma cells. Am J Hematol 1994;45:88.
14. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-9. Epub 2003 Mar 20.
15. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
16. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
17. Stashenko P, Dewhirst FE, Peros WJ, et al. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987;138:1464-8.
18. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991;12:51-6.
19. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004;32:290-2.
20. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001;98:11581-6. Epub 2001 Sep 18.
21. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33.
22. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100:3002-7.
23. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.
24. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005. Epub ahead of print.
25. Nawawi H, Samson D, Apperley J, et al. Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta 1996;253:61-77.
26. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic significance of the carboxy-terminal telopeptide of type 1 collagen (ICTP). Br J Haematol 1997;96:103-10.
27. Abildgaard N, Brixen K, Kristensen JE, et al. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003;120:235-42.
28. Alexandrakis MG, Kyriakou DS, Passam FH, et al. Urinary N-telopeptide levels in multiple myeloma patients, correlation with TC-99M-sesta MIBI scintigraphy and other biochemical markers of disease activity. Hematol Oncol 2003;21:17-24.
29. Elomaa I, Risteli L, Laakso M, et al. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 1996;32A:1166-70.
30. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994;15:41-9.
31. Bosch A, Frias Z. Radiotherapy in the treatment of multiple myeloma. Int J Radiat Oncol Biol Phys 1988;15:1363-9.
32. Adamietz IA, Schober C, Schulte RWM, et al. Palliative radiotherapy in plasma cell myeloma. Radiother Oncol 1991;20:111-6.
33. Rostom AY. A review of the place of radiotherapy in myeloma with emphasis on whole body irradiation. Hematol Oncol 1988;6:193-8.
34. Giles FJ, McSweeney EN, Richards JDM, et al. Prospective randomised study of double hemibody irradiation with and without subsequent maintenance recombinant α2b interferon on survival in patients with relapsed multiple myeloma. Eur J Cancer 1992;28A:1392-5.
35. Lecouvet F, Richard F, Vande Berg B, et al. Long-term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma. Br J Haematol 1997;96:743-5.
36. Catell D, Kogen Z, Donahue B, et al. Multiple myeloma of an extremity: must the entire bone be treated? Int J Radiat Oncol Biol Phys 1998;40:117-9.
37. Giralt S, Bensinger W, Goodman M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003;102:2684-91.
38. Dispenzieri A, Wiseman GA, Lacy MQ, et al. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2004;19:118-25.
39. Iuliano F, Molica S, Abruzzese E, Peta A, Toraldo A, Palermo S. Samarium-153 Sm-EDTMP and zoledronic acid present synergistic action and are able to control pain and significantly improve QOL in elderly patients with multiple myeloma [abstract 6737]. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post Meeting Edition; July 15 Suppl.) 2004.
40. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005;33:784-95.
41. Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop 1989;249:256-64.
42. Healey JH, Brown HK. Complications of bone metastases-surgical management. Cancer 2000;88:2940-51.
43. Barr JD. Point of view: an in vivo comparison of the potential for extravertebral cement leak after vertebroplasty and kyphoplasty. Spine 2002;27:2178-9.
44. Jensen ME, Evans AJ, Mathis JM, et al. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol 1997;18:1897-904.
45. Lieberman IH, Dudeney S, Reinhardt M-K, Bell G. Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine 2001;26:1631-8.
46. Dudeny S, Lieberman IH, Reinhardt M-K, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002;20:2382-7.
47. Lieberman I, Reinhardt MK. Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop 2003;415:5176-86.
48. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-67.
49. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52.
50. Heim ME, Clemens MR, Queisser W, et al. Prospective randomized trial of dicholoromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie 1995;18:439-48.
51. McCloskey EV, MacLennan CM, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998;101:317-25.
52. Menssen HD, Saklova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353-9.
53. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998;101:280-6.
54. Man Z, Otero AB, Rendo P, et al. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990;335:663.
55. Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994;70:554-8.
56. Berenson J, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
57. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
58. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
59. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
60. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
61. Berenson J, Hillner B, Kyle R, et al. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
62. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-7.
63. Takahashi R, Shimazaki C, Inaba T, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001;25:77-83.
64. Chang JT, Green L, Beitz J, Tarassoff P, Hei Y-J, Maladorno D. Renal failure with the use of zoledronic acid [letter to the editor]. N Engl J Med 2003;349:1676-9.
65. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
66. Van Poznak CH, Estilo CL, Sauter NP, et al. Osteonecrosis of the jaw in patients with metastatic breast cancer [abstract]. Breast Cancer Res Treat 2004;88:S131-3057.
67. Hoff AO, Toth B, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Bone Miner Res 2005;20:S55-1218.
68. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99.
69. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 2005;353:100-1.
70. Radl J, Croese JW, Zircher C, et al. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 1985;55:1030-40.
71. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-9.
72. Savage AD, Belson DJ, Vescio RA, et al. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 1996;88:105a.
73. Wood J, Bonjean K, Ruetsz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
74. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
75. Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-4.
76. Ochiai N, Yamada N, Uchida R, et al. Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro. Leuk Lymphoma 2005;46:1619-25.
77. Ochiai N, Yamada N, Uchida R, et al. Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. Int J Hematol 2005;82:243-7.
78. Greipp P, Facon T, Williams CD, et al. A single subcutaneous dose of an osteoprotegerin (OPG) construct (AMGN-0007) causes a profound and sustained decrease in bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma. Blood 2001;98:775a.
79. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6.
80. Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003;97:802-12.
81. Bruzzaniti A, Neff L, Sanjay A, Horne WC, De Camilli P, Baron R. Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity. Mol Biol Cell 2005;16:3301-13. Epub 2005 May 4.
82. de Donk, NWCJ, Lokhorst HM, Nijhuis EHJ, et al. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin Cancer Res 2005;11:429-39.
83. Melton LJ III, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004;19:25-30.